research
Inherited DNA May Shape a CAR-T Course
Whole-genome analysis linked germline variants to treatment activity and toxicity in aggressive lymphoma trials.
Summary
Whole-genome analysis linked germline variants to treatment activity and toxicity in aggressive lymphoma trials.
Researchers analyzed whole genomes from more than 200 people treated with CAR-T cells in two aggressive-lymphoma trials. Variants near STXBP2 correlated with toxicity, ADAMTSL3 variants with protection, and PTPN22 variants with CAR-T expansion and activity. These are associations that need replication; they do not yet justify selecting or withholding treatment from an individual patient.
Why it matters
Whole-genome analysis linked germline variants to treatment activity and toxicity in aggressive lymphoma trials.
Limits and context
- These are associations that need replication; they do not yet justify selecting or withholding treatment from an individual patient.
Key claims
Whole-genome analysis linked germline variants to treatment activity and toxicity in aggressive lymphoma trials.
Qualification: These are associations that need replication; they do not yet justify selecting or withholding treatment from an individual patient.
Evidence: source-2026-07-25-005
Sources
- Mass General Brigham via EurekAlert: Germline genetics and CAR-TMass General Brigham via EurekAlert · secondary reporting
Corrections
No corrections have been recorded for this story.